Cite

    Martin Reck et al.. “Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.” Lung cancer, vol. 90, no. 2, n.d., pp. 267–273. http://access.bl.uk/ark:/81055/vdc_100029218183.0x00001d